Belimumab was approved in recent years for SLE treatment and notably it is the only drug approved for SLE in the last 60 years, since the time corticosteroids, hydroxychloroquine, and nonsteroidal anti-inflammatory drugs were approved for SLE.[14] Two international phase III trials, BLISS-52 and BLISS-76 (ClinicalTrials.gov identifiers NCT00424476 and NCT00410384, respectively) evaluated the safety and efficacy of belimumab in patients with autoantibody-positive (seropositive) SLE (defined as a serum ANA titer of 1:80 and/or positive results on a test for serum anti-dsDNA). Here, BTG3 is linked to systemic lupus erythematosus.